Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.93
+0.04 (0.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
Precision BioSciences Employees
Precision BioSciences had 109 employees as of December 31, 2023. The number of employees decreased by 89 or -44.95% compared to the previous year.
Employees
109
Change (1Y)
-89
Growth (1Y)
-44.95%
Revenue / Employee
$688,954
Profits / Employee
$79,110
Market Cap
45.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
DTIL News
- 3 days ago - Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - Benzinga
- 3 days ago - Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial - Business Wire
- 24 days ago - Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - Business Wire
- 6 weeks ago - Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst - Benzinga
- 6 weeks ago - Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 6 weeks ago - iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 2 months ago - Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B - Business Wire
- 3 months ago - Precision BioSciences to Participate in Upcoming November Investor Conferences - Business Wire